RxDoctor Payments Data

James Demetroulakos, MD

Otolaryngology · Danvers, MANPI 1326011180

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (50.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Inspire Medical Systems, Inc. accounts for 91.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $1,661 and has fallen 84.0% since, to $266 in 2025.

$3,391in general payments, 2019–2025

Across 30 payments — averaging $113.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$3K
  • Medtronic$150
  • Sanofi$77
  • Regeneron Healthcare Solutions, Inc.$29
  • Stryker$21
$25,000in ownership & investment interests, 2019–2025

Across 6 payments — averaging $4166.67 each. An ownership or investment interest held by the physician or an immediate family member.

  • Agile Devices, Inc.$25K

What the payments were for

  • Consulting fees$1504%
  • Travel & lodging$1,52445%
  • Food & beverage$1,71651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,391 in reported general payments places this provider in the 80th percentile of 298 otolaryngology providers in Massachusetts.

See all otolaryngology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$160,559
Medicare patients
758
Services billed
1,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab13$47,393
Azelastine Hcl505$10,453
Famotidine272$3,426
Ipratropium Bromide98$2,148
Dexamethasone18$1,867
Ofloxacin25$1,640
Fluticasone Propionate79$1,310
Fluocinolone Acetonide Oil35$1,201
Hydrocortisone-Acetic AcidHydrocortisone/Acetic Acid14$1,081
Cephalexin49$296
Methylprednisolone29$287
Triamcinolone Acetonide12$221
ValacyclovirValacyclovir Hcl14$161
Doxycycline Monohydrate15$131
Montelukast Sodium11$129

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Danvers

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →